10 Oversold NYSE Stocks to Buy Now

8. Organon & Co. (NYSE:OGN)

YTD Decline: -43.70%

Analyst Upside: 54.76%

Number of Hedge Fund Holders: 28

Organon & Co. (NYSE:OGN) is one of the top oversold NYSE stocks to buy now. Organon & Co. (NYSE:OGN) reported its fiscal Q2 2025 results on August 5, with revenue for the quarter reaching $1.594 billion and diluted earnings per share of $0.56.

GAAP diluted earnings per share for the quarter included a $46 million gain, or $0.14 per share, for early extinguishment of debt.

Organon & Co. (NYSE:OGN) reported net income of $145 million for fiscal Q1 2025, while adjusted EBITDA (non-GAAP) was $522 million, representing an adjusted EBITDA margin of 32.7%.

Management reported that Organon & Co. (NYSE:OGN) repaid $345 million of long-term debt during fiscal Q1 2025, and is on track to attain a net debt to adjusted EBITDA ratio of less than 4.0x by year-end.

The company also raised its revenue guidance range for the full year 2025 to $6.275 billion to $6.375 billion, based on its current views of foreign exchange. Organon & Co. (NYSE:OGN) affirmed the guidance range for adjusted EBITDA margin (non-GAAP) at 31.0% to 32.0%.

Organon & Co. (NYSE:OGN) is a global pharmaceutical company that develops and delivers innovative health solutions via a portfolio of prescription therapies within women’s health, established brands, and biosimilars.